Papillomavirus Infections Clinical Trial
Official title:
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the Prevention of Oral Persistent Infection With HPV Types 16, 18, 31, 33, 45, 52, or 58 in Adult Males, 20 to 45 Years of Age
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of HPV 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo. There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
| Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
| Completed |
NCT06399341 -
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
|
||
| Recruiting |
NCT03548740 -
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
|
||
| Completed |
NCT00092547 -
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
|
Phase 3 | |
| Completed |
NCT00157950 -
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT00365729 -
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
|
N/A | |
| Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
| Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
| Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
| Completed |
NCT00549250 -
Human Papillomavirus 6/11 in the Lower Airway of Neonates
|
N/A | |
| Recruiting |
NCT04694495 -
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
|
||
| Completed |
NCT06439433 -
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
|
Phase 2 | |
| Completed |
NCT00380367 -
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
|
Phase 3 | |
| Completed |
NCT01894425 -
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation
|
N/A | |
| Completed |
NCT00685412 -
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
|
Phase 1 | |
| Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT04772534 -
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
|
Phase 3 | |
| Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
| Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 |